{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T22:30:56Z","timestamp":1787265056023,"version":"build-2736575974"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T00:00:00Z","timestamp":1730246400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T00:00:00Z","timestamp":1730246400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100007537","name":"Freie Universit\u00e4t Berlin","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007537","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1007\/s40262-024-01434-8","type":"journal-article","created":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T12:15:01Z","timestamp":1730290501000},"page":"1609-1630","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Understanding Voriconazole Metabolism: A Middle-Out Physiologically-Based Pharmacokinetic Modelling Framework Integrating In Vitro and Clinical Insights"],"prefix":"10.1007","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8161-9854","authenticated-orcid":false,"given":"Ayatallah","family":"Saleh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0968-5873","authenticated-orcid":false,"given":"Josefine","family":"Schulz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan-Frederik","family":"Schlender","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4840-5704","authenticated-orcid":false,"given":"Linda B. S.","family":"Aulin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-2692-7061","authenticated-orcid":false,"given":"Amrei-Pauline","family":"Konrad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5985-9683","authenticated-orcid":false,"given":"Franziska","family":"Kluwe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1783-133X","authenticated-orcid":false,"given":"Gerd","family":"Mikus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5249-3914","authenticated-orcid":false,"given":"Wilhelm","family":"Huisinga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9344-8514","authenticated-orcid":false,"given":"Charlotte","family":"Kloft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5485-607X","authenticated-orcid":false,"given":"Robin","family":"Michelet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,30]]},"reference":[{"key":"1434_CR1","doi-asserted-by":"publisher","first-page":"271","DOI":"10.3238\/arztebl.2019.0271","volume":"116","author":"M von Lilienfeld-Toal","year":"2019","unstructured":"von Lilienfeld-Toal M, Wagener J, Einsele H, et al. Invasive fungal infection. Dtsch Arztebl Int. 2019;116:271\u20138. https:\/\/doi.org\/10.3238\/arztebl.2019.0271.","journal-title":"Dtsch Arztebl Int"},{"key":"1434_CR2","doi-asserted-by":"publisher","first-page":"e383","DOI":"10.1016\/S1473-3099(17)30316-X","volume":"17","author":"DS Perlin","year":"2017","unstructured":"Perlin DS, Rautemaa-Richardson R, Alastruey-Izquierdo A. The global problem of antifungal resistance: prevalence, mechanisms, and management. Lancet Infect Dis. 2017;17:e383\u201392.","journal-title":"Lancet Infect Dis"},{"key":"1434_CR3","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1128\/CMR.12.4.501","volume":"12","author":"MA Ghannoum","year":"1999","unstructured":"Ghannoum MA, Rice LB. Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. Clin Microbiol Rev. 1999;12:501\u201317. https:\/\/doi.org\/10.1128\/CMR.12.4.501.","journal-title":"Clin Microbiol Rev"},{"key":"1434_CR4","volume-title":"VFEND summary of product characteristics (SmPC)","author":"Pfizer","year":"2020","unstructured":"Pfizer. VFEND summary of product characteristics (SmPC). Pfizer; 2020."},{"key":"1434_CR5","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1345\/aph.1C261","volume":"37","author":"MM Pearson","year":"2003","unstructured":"Pearson MM, Rogers PD, Cleary JD, Chapman SW. Voriconazole: a new triazole antifungal agent. Ann Pharmacother. 2003;37:420\u201332. https:\/\/doi.org\/10.1345\/aph.1C261.","journal-title":"Ann Pharmacother"},{"key":"1434_CR6","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.3324\/haematol.2009.020073","volume":"95","author":"C Cordonnier","year":"2010","unstructured":"Cordonnier C, Rovira M, Maertens J, et al. Voriconazole for secondary prophylaxis of invasive fungal infections in allogeneic stem cell transplant recipients: results of the VOSIFI study. Haematologica. 2010;95:1762\u20138. https:\/\/doi.org\/10.3324\/haematol.2009.020073.","journal-title":"Haematologica"},{"key":"1434_CR7","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1111\/j.1365-2141.2011.08838.x","volume":"155","author":"DI Marks","year":"2011","unstructured":"Marks DI, Pagliuca A, Kibbler CC, et al. Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stem-cell transplantation. Br J Haematol. 2011;155:318\u201327. https:\/\/doi.org\/10.1111\/j.1365-2141.2011.08838.x.","journal-title":"Br J Haematol"},{"key":"1434_CR8","doi-asserted-by":"publisher","first-page":"2546","DOI":"10.1128\/AAC.46.8.2546-2553.2002","volume":"46","author":"L Purkins","year":"2002","unstructured":"Purkins L, Wood N, Ghahramani P, et al. Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens. Antimicrob Agents Chemother. 2002;46:2546\u201353. https:\/\/doi.org\/10.1128\/AAC.46.8.2546-2553.2002.","journal-title":"Antimicrob Agents Chemother"},{"key":"1434_CR9","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/J.EJPS.2019.02.001","volume":"131","author":"C Kirbs","year":"2019","unstructured":"Kirbs C, Kluwe F, Drescher F, et al. High voriconazole target-site exposure after approved sequence dosing due to nonlinear pharmacokinetics assessed by long-term microdialysis. Eur J Pharm Sci. 2019;131:218\u201329. https:\/\/doi.org\/10.1016\/J.EJPS.2019.02.001.","journal-title":"Eur J Pharm Sci"},{"key":"1434_CR10","doi-asserted-by":"publisher","first-page":"649","DOI":"10.2165\/00003088-200645070-00002","volume":"45","author":"U Theuretzbacher","year":"2006","unstructured":"Theuretzbacher U, Ihle F, Derendorf H. Pharmacokinetic\/pharmacodynamic profile of voriconazole. Clin Pharmacokinet. 2006;45:649\u201363. https:\/\/doi.org\/10.2165\/00003088-200645070-00002.","journal-title":"Clin Pharmacokinet"},{"key":"1434_CR11","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1080\/03602532.2019.1632888","volume":"51","author":"J Schulz","year":"2019","unstructured":"Schulz J, Kluwe F, Mikus G, et al. Novel insights into the complex pharmacokinetics of voriconazole: a review of its metabolism. Drug Metab Rev. 2019;51:247\u201365. https:\/\/doi.org\/10.1080\/03602532.2019.1632888.","journal-title":"Drug Metab Rev"},{"key":"1434_CR12","doi-asserted-by":"publisher","first-page":"2592","DOI":"10.1093\/jac\/dkt229","volume":"68","author":"MJP Geist","year":"2013","unstructured":"Geist MJP, Egerer G, Burhenne J, et al. Steady-state pharmacokinetics and metabolism of voriconazole in patients. J Antimicrob Chemother. 2013;68:2592\u20139. https:\/\/doi.org\/10.1093\/jac\/dkt229.","journal-title":"J Antimicrob Chemother"},{"key":"1434_CR13","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1007\/s40262-016-0416-1","volume":"55","author":"N Hohmann","year":"2016","unstructured":"Hohmann N, Kocheise F, Carls A, et al. Dose-dependent bioavailability and CYP3A inhibition contribute to non-linear pharmacokinetics of voriconazole. Clin Pharmacokinet. 2016;55:1535\u201345. https:\/\/doi.org\/10.1007\/s40262-016-0416-1.","journal-title":"Clin Pharmacokinet"},{"key":"1434_CR14","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1111\/j.1365-2125.2009.03534.x","volume":"68","author":"I Scholz","year":"2009","unstructured":"Scholz I, Oberwittler H, Riedel K-D, et al. Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype. Br J Clin Pharmacol. 2009;68:906\u201315. https:\/\/doi.org\/10.1111\/j.1365-2125.2009.03534.x.","journal-title":"Br J Clin Pharmacol"},{"key":"1434_CR15","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1111\/bcp.14661","volume":"87","author":"E Gautier-Veyret","year":"2021","unstructured":"Gautier-Veyret E, Thiebaut-Bertrand A, Roustit M, et al. Optimization of voriconazole therapy for treatment of invasive aspergillosis: Pharmacogenomics and inflammatory status need to be evaluated. Br J Clin Pharmacol. 2021;87:2534\u201341. https:\/\/doi.org\/10.1111\/bcp.14661.","journal-title":"Br J Clin Pharmacol"},{"key":"1434_CR16","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1128\/AAC.04838-14","volume":"59","author":"E Gautier-Veyret","year":"2015","unstructured":"Gautier-Veyret E, Fonrose X, Tonini J, et al. Variability of voriconazole plasma concentrations after allogeneic hematopoietic stem cell transplantation: impact of cytochrome p450 polymorphisms and comedications on initial and subsequent trough levels. Antimicrob Agents Chemother. 2015;59:2305\u201314. https:\/\/doi.org\/10.1128\/AAC.04838-14.","journal-title":"Antimicrob Agents Chemother"},{"key":"1434_CR17","doi-asserted-by":"publisher","first-page":"477","DOI":"10.3390\/pharmaceutics14030477","volume":"14","author":"J Schulz","year":"2022","unstructured":"Schulz J, Thomas A, Saleh A, et al. Towards the elucidation of the pharmacokinetics of voriconazole: a quantitative characterization of its metabolism. Pharmaceutics. 2022;14:477. https:\/\/doi.org\/10.3390\/pharmaceutics14030477.","journal-title":"Pharmaceutics"},{"key":"1434_CR18","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1124\/dmd.31.6.731","volume":"31","author":"SJ Roffey","year":"2003","unstructured":"Roffey SJ, Cole S, Comby P, et al. The disposition of voriconazole in mouse, rat, rabbit, guinea pig, dog, and human. Drug Metab Dispos. 2003;31:731\u201341. https:\/\/doi.org\/10.1124\/dmd.31.6.731.","journal-title":"Drug Metab Dispos"},{"key":"1434_CR19","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.medmal.2011.09.016","volume":"41","author":"O Epaulard","year":"2011","unstructured":"Epaulard O, Leccia M-T, Blanche S, et al. Phototoxicity and photocarcinogenesis associated with voriconazole. Med Mal Infect. 2011;41:639\u201345. https:\/\/doi.org\/10.1016\/j.medmal.2011.09.016.","journal-title":"Med Mal Infect"},{"key":"1434_CR20","doi-asserted-by":"publisher","first-page":"e182","DOI":"10.1093\/cid\/cit600","volume":"57","author":"O Epaulard","year":"2013","unstructured":"Epaulard O, Villier C, Ravaud P, et al. A multistep voriconazole-related phototoxic pathway may lead to skin carcinoma: results from a French nationwide study. Clin Infect Dis. 2013;57:e182\u20138. https:\/\/doi.org\/10.1093\/cid\/cit600.","journal-title":"Clin Infect Dis"},{"key":"1434_CR21","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1093\/infdis\/jiu017","volume":"209","author":"D Zonios","year":"2014","unstructured":"Zonios D, Yamazaki H, Murayama N, et al. Voriconazole metabolism, toxicity, and the effect of cytochrome P450 2C19 genotype. J Infect Dis. 2014;209:1941\u20138. https:\/\/doi.org\/10.1093\/infdis\/jiu017.","journal-title":"J Infect Dis"},{"key":"1434_CR22","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1128\/AAC.01123-08","volume":"53","author":"S Jeong","year":"2009","unstructured":"Jeong S, Nguyen PD, Desta Z. Comprehensive in vitro analysis of voriconazole inhibition of eight cytochrome P450 (CYP) enzymes: major effect on CYPs 2B6, 2C9, 2C19, and 3A. Antimicrob Agents Chemother. 2009;53:541\u201351. https:\/\/doi.org\/10.1128\/AAC.01123-08.","journal-title":"Antimicrob Agents Chemother"},{"key":"1434_CR23","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1248\/bpb.28.1805","volume":"28","author":"T Niwa","year":"2005","unstructured":"Niwa T, Shiraga T, Takagi A. Effect of antifungal drugs on cytochrome P450 (CYP) 2C9, CYP2C19, and CYP3A4 activities in human liver microsomes. Biol Pharm Bull. 2005;28:1805\u20138. https:\/\/doi.org\/10.1248\/bpb.28.1805.","journal-title":"Biol Pharm Bull"},{"key":"1434_CR24","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1248\/bpb.28.1813","volume":"28","author":"T Niwa","year":"2005","unstructured":"Niwa T, Inoue-Yamamoto S, Shiraga T, Takagi A. Effect of antifungal drugs on cytochrome P450 (CYP) 1A2, CYP2D6, and CYP2E1 activities in human liver microsomes. Biol Pharm Bull. 2005;28:1813\u20136. https:\/\/doi.org\/10.1248\/bpb.28.1813.","journal-title":"Biol Pharm Bull"},{"key":"1434_CR25","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1007\/S40262-022-01175-6","volume":"61","author":"YM Nassar","year":"2022","unstructured":"Nassar YM, Hohmann N, Michelet R, et al. Quantification of the time course of CYP3A inhibition, activation, and induction using a population pharmacokinetic model of microdosed midazolam continuous infusion. Clin Pharmacokinet. 2022;61:1595. https:\/\/doi.org\/10.1007\/S40262-022-01175-6.","journal-title":"Clin Pharmacokinet"},{"key":"1434_CR26","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1517\/14740330903485637","volume":"9","author":"AC Pasqualotto","year":"2010","unstructured":"Pasqualotto AC, Xavier MO, Andreolla HF, Linden R. Voriconazole therapeutic drug monitoring: focus on safety. Expert Opin Drug Saf. 2010;9:125\u201337. https:\/\/doi.org\/10.1517\/14740330903485637.","journal-title":"Expert Opin Drug Saf"},{"key":"1434_CR27","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.1007\/s11095-022-03407-7","volume":"39","author":"J Schulz","year":"2022","unstructured":"Schulz J, Michelet R, Zeitlinger M, et al. Microdialysis of voriconazole and its N-oxide metabolite: amalgamating knowledge of distribution and metabolism processes in humans. Pharm Res. 2022;39:3279\u201391. https:\/\/doi.org\/10.1007\/s11095-022-03407-7.","journal-title":"Pharm Res"},{"key":"1434_CR28","doi-asserted-by":"publisher","first-page":"695","DOI":"10.5414\/CPP48695","volume":"48","author":"F Simmel","year":"2010","unstructured":"Simmel F, Kloft C. Microdialysis feasibility investigations with the non-hydrophilic antifungal voriconazole for potential applications in nonclinical and clinical settings. Int J Clin Pharmacol Ther. 2010;48:695\u2013704. https:\/\/doi.org\/10.5414\/CPP48695.","journal-title":"Int J Clin Pharmacol Ther"},{"key":"1434_CR29","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s00216-008-2286-3","volume":"392","author":"F Simmel","year":"2008","unstructured":"Simmel F, Soukup J, Zoerner A, et al. Development and validation of an efficient HPLC method for quantification of voriconazole in plasma and microdialysate reflecting an important target site. Anal Bioanal Chem. 2008;392:479\u201388. https:\/\/doi.org\/10.1007\/s00216-008-2286-3.","journal-title":"Anal Bioanal Chem"},{"key":"1434_CR30","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1111\/bcp.13297","volume":"83","author":"N Hohmann","year":"2017","unstructured":"Hohmann N, Kreuter R, Blank A, et al. Autoinhibitory properties of the parent but not of the N-oxide metabolite contribute to infusion rate-dependent voriconazole pharmacokinetics. Br J Clin Pharmacol. 2017;83:1954\u201365. https:\/\/doi.org\/10.1111\/bcp.13297.","journal-title":"Br J Clin Pharmacol"},{"key":"1434_CR31","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1248\/bpb.b15-00241","volume":"38","author":"T Yamada","year":"2015","unstructured":"Yamada T, Mino Y, Yagi T, et al. Saturated metabolism of voriconazole N-oxidation resulting in nonlinearity of pharmacokinetics of voriconazole at clinical doses. Biol Pharm Bull. 2015;38:1496\u2013503. https:\/\/doi.org\/10.1248\/bpb.b15-00241.","journal-title":"Biol Pharm Bull"},{"key":"1434_CR32","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1177\/0091270008327537","volume":"49","author":"J Weiss","year":"2009","unstructured":"Weiss J, Ten Hoevel MM, Burhenne J, et al. CYP2C19 genotype is a major factor contributing to the highly variable pharmacokinetics of voriconazole. J Clin Pharmacol. 2009;49:196\u2013204. https:\/\/doi.org\/10.1177\/0091270008327537.","journal-title":"J Clin Pharmacol"},{"key":"1434_CR33","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1002\/cpt.583","volume":"102","author":"B Moriyama","year":"2017","unstructured":"Moriyama B, Obeng AO, Barbarino J, et al. Clinical pharmacogenetics implementation consortium (CPIC) guidelines for CYP2C19 and voriconazole therapy. Clin Pharmacol Ther. 2017;102:45\u201351. https:\/\/doi.org\/10.1002\/cpt.583.","journal-title":"Clin Pharmacol Ther"},{"key":"1434_CR34","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1007\/s40262-019-00856-z","volume":"59","author":"X Li","year":"2020","unstructured":"Li X, Frechen S, Moj D, et al. A physiologically based pharmacokinetic model of voriconazole integrating time-dependent inhibition of CYP3A4, genetic polymorphisms of CYP2C19 and predictions of drug-drug interactions. Clin Pharmacokinet. 2020;59:781\u2013808. https:\/\/doi.org\/10.1007\/s40262-019-00856-z.","journal-title":"Clin Pharmacokinet"},{"key":"1434_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.636097","volume":"12","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Zhao S, Wang C, et al. Application of a physiologically based pharmacokinetic model to characterize time-dependent metabolism of voriconazole in children and support dose optimization. Front Pharmacol. 2021;12: 636097. https:\/\/doi.org\/10.3389\/fphar.2021.636097.","journal-title":"Front Pharmacol"},{"key":"1434_CR36","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1007\/s11095-022-03289-9","volume":"39","author":"J Dong","year":"2022","unstructured":"Dong J, Liu S-B, Rasheduzzaman JM, et al. Development of physiology based pharmacokinetic model to predict the drug interactions of voriconazole and venetoclax. Pharm Res. 2022;39:1921\u201333. https:\/\/doi.org\/10.1007\/s11095-022-03289-9.","journal-title":"Pharm Res"},{"key":"1434_CR37","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1046\/J.1365-2125.2003.01992.X","volume":"56","author":"L Purkins","year":"2003","unstructured":"Purkins L, Wood N, Greenhalgh K, et al. The pharmacokinetics and safety of intravenous voriconazole\u2014a novel wide-spectrum antifungal agent. Br J Clin Pharmacol. 2003;56:2. https:\/\/doi.org\/10.1046\/J.1365-2125.2003.01992.X.","journal-title":"Br J Clin Pharmacol"},{"key":"1434_CR38","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1002\/jps.20073","volume":"93","author":"LM Berezhkovskiy","year":"2004","unstructured":"Berezhkovskiy LM. Volume of distribution at steady state for a linear pharmacokinetic system with peripheral elimination. J Pharm Sci. 2004;93:1628\u201340. https:\/\/doi.org\/10.1002\/jps.20073.","journal-title":"J Pharm Sci"},{"key":"1434_CR39","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.clpt.2005.01.024","volume":"78","author":"J Rengelshausen","year":"2005","unstructured":"Rengelshausen J, Banfield M, Riedel K-D, et al. Opposite effects of short-term and long-term St John\u2019s wort intake on voriconazole pharmacokinetics. Clin Pharmacol Ther. 2005;78:25\u201333. https:\/\/doi.org\/10.1016\/j.clpt.2005.01.024.","journal-title":"Clin Pharmacol Ther"},{"key":"1434_CR40","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1124\/dmd.111.043174","volume":"40","author":"M Meyer","year":"2012","unstructured":"Meyer M, Schneckener S, Ludewig B, et al. Using expression data for quantification of active processes in physiologically based pharmacokinetic modeling. Drug Metab Dispos. 2012;40:892\u2013901. https:\/\/doi.org\/10.1124\/dmd.111.043174.","journal-title":"Drug Metab Dispos"},{"key":"1434_CR41","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1124\/dmd.113.055632","volume":"42","author":"B Achour","year":"2014","unstructured":"Achour B, Russell MR, Barber J, Rostami-Hodjegan A. Simultaneous quantification of the abundance of several cytochrome P450 and uridine 5\u2032-diphospho-glucuronosyltransferase enzymes in human liver microsomes using multiplexed targeted proteomics. Drug Metab Dispos. 2014;42:500\u201310. https:\/\/doi.org\/10.1124\/dmd.113.055632.","journal-title":"Drug Metab Dispos"},{"key":"1434_CR42","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1016\/j.bcp.2007.03.012","volume":"73","author":"N Murayama","year":"2007","unstructured":"Murayama N, Imai N, Nakane T, et al. Roles of CYP3A4 and CYP2C19 in methyl hydroxylated and N-oxidized metabolite formation from voriconazole, a new anti-fungal agent, in human liver microsomes. Biochem Pharmacol. 2007;73:2020\u20136. https:\/\/doi.org\/10.1016\/j.bcp.2007.03.012.","journal-title":"Biochem Pharmacol"},{"key":"1434_CR43","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.730826","volume":"12","author":"S Li","year":"2021","unstructured":"Li S, Wu S, Gong W, et al. Application of population pharmacokinetic analysis to characterize CYP2C19 mediated metabolic mechanism of voriconazole and support dose optimization. Front Pharmacol. 2021;12: 730826. https:\/\/doi.org\/10.3389\/fphar.2021.730826.","journal-title":"Front Pharmacol"},{"key":"1434_CR44","volume-title":"Enzyme kinetics: behavior and analysis of rapid equilibrium and steady-state enzyme systems","author":"IH Segel","year":"1975","unstructured":"Segel IH. Enzyme kinetics: behavior and analysis of rapid equilibrium and steady-state enzyme systems. Wiley-Blackwell; 1975."},{"key":"1434_CR45","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s10928-007-9053-5","volume":"34","author":"S Willmann","year":"2007","unstructured":"Willmann S, H\u00f6hn K, Edginton A, et al. Development of a physiology-based whole-body population model for assessing the influence of individual variability on the pharmacokinetics of drugs. J Pharmacokinet Pharmacodyn. 2007;34:401\u201331. https:\/\/doi.org\/10.1007\/s10928-007-9053-5.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"1434_CR46","unstructured":"Open Systems Pharmacology Suite Community. PK-Sim\u00ae Ontogeny Database Documentation, Version 7.3. 2018. Available at: https:\/\/github.com\/Open-Systems-Pharmacology\/OSPSuite.Documentation\/blob\/master\/PK-SimOntogenyDatabaseVersion7.3.pdf."},{"key":"1434_CR47","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1002\/psp4.12473","volume":"8","author":"J Lippert","year":"2019","unstructured":"Lippert J, Burghaus R, Edginton A, et al. Open systems pharmacology community-an open access, open source, open science approach to modeling and simulation in pharmaceutical sciences. CPT pharmacometrics Syst Pharmacol. 2019;8:878\u201382. https:\/\/doi.org\/10.1002\/psp4.12473.","journal-title":"CPT pharmacometrics Syst Pharmacol"},{"key":"1434_CR48","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3389\/fphys.2011.00004","volume":"2","author":"T Eissing","year":"2011","unstructured":"Eissing T, Kuepfer L, Becker C, et al. A computational systems biology software platform for multiscale modeling and simulation: integrating whole-body physiology, disease biology, and molecular reaction networks. Front Physiol. 2011;2:4. https:\/\/doi.org\/10.3389\/fphys.2011.00004.","journal-title":"Front Physiol"},{"key":"1434_CR49","unstructured":"Ankit Rohatgi. WebPlotDigitizer. 2022. Available at: https:\/\/automeris.io\/WebPlotDigitizer\/. Accessed 4 Dec 2022"},{"key":"1434_CR50","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1002\/psp4.12511","volume":"9","author":"J-G Wojtyniak","year":"2020","unstructured":"Wojtyniak J-G, Britz H, Selzer D, et al. Data digitizing: accurate and precise data extraction for quantitative systems pharmacology and physiologically-based pharmacokinetic modeling. CPT Pharmacomet Syst Pharmacol. 2020;9:322\u201331. https:\/\/doi.org\/10.1002\/psp4.12511.","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"key":"1434_CR51","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1007\/s40262-014-0181-y","volume":"53","author":"NR Zane","year":"2014","unstructured":"Zane NR, Thakker DR. A physiologically based pharmacokinetic model for voriconazole disposition predicts intestinal first-pass metabolism in children. Clin Pharmacokinet. 2014;53:1171\u201382. https:\/\/doi.org\/10.1007\/s40262-014-0181-y.","journal-title":"Clin Pharmacokinet"},{"key":"1434_CR52","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s11095-021-03019-7","volume":"38","author":"F Simon","year":"2021","unstructured":"Simon F, Gautier-Veyret E, Truffot A, et al. Modeling approach to predict the impact of inflammation on the pharmacokinetics of CYP2C19 and CYP3A4 substrates. Pharm Res. 2021;38:415\u201328. https:\/\/doi.org\/10.1007\/s11095-021-03019-7.","journal-title":"Pharm Res"},{"key":"1434_CR53","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1007\/S40262-023-01287-7\/FIGURES\/5","volume":"62","author":"A Muhareb","year":"2023","unstructured":"Muhareb A, Blank A, Meid AD, et al. CYP3A and CYP2C19 activity determined by microdosed probe drugs accurately predict voriconazole clearance in healthy adults. Clin Pharmacokinet. 2023;62:1305\u201314. https:\/\/doi.org\/10.1007\/S40262-023-01287-7\/FIGURES\/5.","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"1434_CR54","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1002\/cpt.3222","volume":"116","author":"P Wang","year":"2024","unstructured":"Wang P, Liu S, Yang J. Physiologically based pharmacokinetic modeling to investigate the disease-drug-drug interactions between voriconazole and nirmatrelvir\/ritonavir in COVID-19 patients with CYP2C19 phenotypes. Clin Pharmacol Ther. 2024;116(2):363\u201371. https:\/\/doi.org\/10.1002\/cpt.3222.","journal-title":"Clin Pharmacol Ther"},{"key":"1434_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-1-62703-758-7_1","volume":"1113","author":"S Nagar","year":"2014","unstructured":"Nagar S, Argikar UA, Tweedie DJ. Enzyme kinetics in drug metabolism: fundamentals and applications. Methods Mol Biol. 2014;1113:1\u20136. https:\/\/doi.org\/10.1007\/978-1-62703-758-7_1.","journal-title":"Methods Mol Biol"},{"key":"1434_CR56","doi-asserted-by":"publisher","first-page":"2991","DOI":"10.1007\/s11095-022-03292-0","volume":"39","author":"J Schulz","year":"2022","unstructured":"Schulz J, Michelet R, Zeitlinger M, et al. Microdialysis of drug and drug metabolite: a comprehensive in vitro analysis for voriconazole and voriconazole N-oxide. Pharm Res. 2022;39:2991\u20133003. https:\/\/doi.org\/10.1007\/s11095-022-03292-0.","journal-title":"Pharm Res"},{"issue":"10","key":"1434_CR57","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1007\/s40262-023-01274-y","volume":"62","author":"F Kluwe","year":"2023","unstructured":"Kluwe F, Michelet R, Huisinga W, et al. Towards model-informed precision dosing of voriconazole: challenging published voriconazole nonlinear mixed-effects models with real-world clinical data. Clin Pharmacokinet. 2023;62(10):1461\u201377. https:\/\/doi.org\/10.1007\/s40262-023-01274-y.","journal-title":"Clin Pharmacokinet"},{"key":"1434_CR58","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1002\/cpt.2049","volume":"109","author":"F Kluwe","year":"2021","unstructured":"Kluwe F, Michelet R, Mueller-Schoell A, et al. Perspectives on model-informed precision dosing in the digital health era: challenges, opportunities, and recommendations. Clin Pharmacol Ther. 2021;109:29\u201336. https:\/\/doi.org\/10.1002\/cpt.2049.","journal-title":"Clin Pharmacol Ther"},{"issue":"Suppl 1","key":"1434_CR59","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1046\/j.1365-2125.2003.01992.x","volume":"56","author":"L Purkins","year":"2003","unstructured":"Purkins L, Wood N, Greenhalgh K, et al. The pharmacokinetics and safety of intravenous voriconazole\u2014a novel wide-spectrum antifungal agent. Br J Clin Pharmacol. 2003;56(Suppl 1):2\u20139. https:\/\/doi.org\/10.1046\/j.1365-2125.2003.01992.x.","journal-title":"Br J Clin Pharmacol"},{"key":"1434_CR60","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1002\/jps.24064","volume":"103","author":"K Vanstraelen","year":"2014","unstructured":"Vanstraelen K, Wauters J, De Loor H, et al. Protein-binding characteristics of voriconazole determined by high-throughput equilibrium dialysis. J Pharm Sci. 2014;103:2565\u201370. https:\/\/doi.org\/10.1002\/jps.24064.","journal-title":"J Pharm Sci"},{"key":"1434_CR61","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s40262-020-00941-8","volume":"60","author":"P Zubiaur","year":"2021","unstructured":"Zubiaur P, Kneller LA, Ochoa D, et al. Evaluation of voriconazole CYP2C19 phenotype-guided dose adjustments by physiologically based pharmacokinetic modeling. Clin Pharmacokinet. 2021;60:261\u201370. https:\/\/doi.org\/10.1007\/s40262-020-00941-8.","journal-title":"Clin Pharmacokinet"},{"key":"1434_CR62","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1002\/psp4.12343","volume":"7","author":"N Hanke","year":"2018","unstructured":"Hanke N, Frechen S, Moj D, et al. PBPK models for CYP3A4 and P-gp DDI Prediction: A modeling network of rifampicin, itraconazole, clarithromycin, midazolam, alfentanil, and digoxin. CPT Pharmacometrics Syst Pharmacol. 2018;7:647\u201359. https:\/\/doi.org\/10.1002\/psp4.12343.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"1434_CR63","unstructured":"PK-Sim Ontogeny Database, Version 7.3. 2018. Available at: https:\/\/github.com\/Open-Systems-Pharmacology\/OSPSuite.Documentation\/blob\/master\/PK-SimOntogeny Database Version 7.3.pdf. Accessed 5 Dec 2020"},{"key":"1434_CR64","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1248\/yakushi.123.369","volume":"123","author":"M Nishimura","year":"2003","unstructured":"Nishimura M, Yaguti H, Yoshitsugu H, et al. Tissue distribution of mRNA expression of human cytochrome P450 isoforms assessed by high-sensitivity real-time reverse transcription PCR. Yakugaku Zasshi. 2003;123:369\u201375. https:\/\/doi.org\/10.1248\/yakushi.123.369.","journal-title":"Yakugaku Zasshi"},{"key":"1434_CR65","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1124\/dmd.31.7.945","volume":"31","author":"K Ito","year":"2003","unstructured":"Ito K, Ogihara K, Kanamitsu S-I, Itoh T. Prediction of the in vivo interaction between midazolam and macrolides based on in vitro studies using human liver microsomes. Drug Metab Dispos. 2003;31:945\u201354. https:\/\/doi.org\/10.1124\/dmd.31.7.945.","journal-title":"Drug Metab Dispos"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-024-01434-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-024-01434-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-024-01434-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T23:39:06Z","timestamp":1757115546000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-024-01434-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,30]]},"references-count":65,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["1434"],"URL":"https:\/\/doi.org\/10.1007\/s40262-024-01434-8","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,30]]},"assertion":[{"value":"30 September 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Open Access funding was enabled and organised by Projekt DEAL.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Charlotte Kloft and Wilhelm Huisinga report grants from an industry consortium (AbbVie Deutschland GmbH & Co. K.G., AstraZeneca, Boehringer Ingelheim Pharma GmbH & Co. K.G., Gr\u00fcnenthal GmbH, F. Hoffmann-La Roche Ltd, Merck KGaA, Novo Nordisk A\/S and Sanofi) for the graduate research training programme PharMetrX. In addition, Charlotte Kloft reports research grants from the Innovative Medicines Initiative-Joint Undertaking (\u2018DDMoRe\u2019), from H2020-EU.3.1.3 (\u2018FAIR\u2019), Diurnal Ltd and the Federal Ministry of Education and Research within the Joint Programming Initiative on Antimicrobial Resistance Initiative (\u2018JPIAMR\u2019), all outside the submitted work. Ayatallah Saleh, Josefine Schulz, Jan-Frederik Schlender, Linda B.S. Aulin, Amrei-Pauline Konrad, Franziska Kluwe, Gerd Mikus, and Robin Michelet declare no competing interests that may be relevant to the contents of this work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. All trial protocols were approved by the responsible Ethics Committees and the respective competent authorities.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Written informed consent was obtained from all individual study participants before inclusion. Written informed consent was obtained from all individual study participants before inclusion.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}},{"value":"The datasets generated and\/or analysed during the current study are not publicly available as patients did not provide consent for sharing their data in a public database. The datasets are available from the corresponding author upon reasonable request.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"The PBPK model will be available on the AK-Kloft GitHub website and can be freely downloaded.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Code"}},{"value":"Conceptualisation: AS, RM, CK. Clinical data collection: GM, CK.\n                      In vitro\n                      data generation: JS, CK. Planning of analysis: AS, FK, RM, CK. Formal analysis and investigation: AS, RM, JFS, WH, GM, CK. Writing \u2013 original draft preparation: AS, RM. Writing \u2013 review and editing: All authors contributed to discussion of the results as well as reviewing and editing the manuscript.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}